NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘Third Rock Ventures’

1 July 2014

Venture firms back $34m Series D for anti-heart failure device maker DC Devices

heart monitor medical healthcare A trio of venture capital firms have taken part in a $34m Series D funding round for DC Devices, which makes equipment designed to help treat heart failure.

22 May 2014

Nurix raises $25.1m Series B from Third Rock, The Column Group

biotech_lrg Third Rock Ventures and The Column Group have invested $25.1m in Series B capital in biotec startup Nurix, which is focused on developing therapies that modulate the ubiquitin proteasome system.

23 April 2014

Kala Pharmaceuticals scores $22.5m Series B

dollar envelope money Ysios Capital has led a $22.5m Series B round for Kala Pharmaceuticals, which is focused on developing ophthalmic products based on its mucus penetrating particle technology.

16 April 2014

Biopharma developer PanOptica scores $45m Series B investment

Biopharmaceutical company PanOptica has raised up to $45m in a Series B financing, co-led by new participant Novo Ventures and existing investor Third Rock Ventures, alongside founding investor SV Life Sciences.

20 March 2014

Third Rock, Prospect Ventures return for $34m NinePoint Medical Series B

surgey-operation-medical-healthcare-doctor-patient-hospital NinePoint Medical founding investors Third Rock Ventures and Prospect Venture Partners have renewed their commitment to the company by backing a $34m financing round.

13 March 2014

OrbiMed helps Sage Therapeutics raise $38m

medical monitor Healthcare-focused investment firm OrbiMed Advisors participated in a $38m Series C round for biopharmaceutical company Sage Therapeutics.

7 February 2014

Eleven Biotherapeutics raises $50m via IPO

dollar envelope money Venture capital-backed biopharmaceutical company Eleven Biotherapeutics has raised $50m via an IPO on the Nasdaq exchange.

25 November 2013

Flagship, Polaris, Third Rock lead $43m Series A for Editas Medicine

biotech_lrg Flagship Ventures, Polaris Partners and Third Rock Ventures have led a $43m Series A for genome editing specialist Editas Medicine.

16 October 2013

SAGE Therapeutics raises $20m from Arch Venture Partners, Third Rock

pharmaceutical 12_sq Arch Venture Partners and Third Rock Ventures have invested $20m in SAGE Therapeutics, bringing the biopharmaceutical company’s fundraising total to $57.8m.

30 July 2013

New Enterprise Associates leads $16m Series B for Edimer Pharmaceuticals

Venture capital firm New Enterprise Associates has led an $18m Series B round fro biotechnology startup Edimer Pharmaceuticals.

Page 1 of 212

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014